U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07064005) titled 'Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.' on June 27.
Brief Summary: This study is designed as an open-label, single-center, clinical trial to evaluate the effects of GGC supplementation in confirmed Parkinson's Disease patients. The main objectives of the study are to evaluate:
1. the change in glutathione (GSH) levels in brain and blood.
2. the change in motor function, cognitive skills and emotional well being in people with Parkinson's Disease.
3. whether GGC will reduce dysbiosis of the gut microbiome.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condi...